Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Open Access
- 4 April 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (9), e194-e199
- https://doi.org/10.1093/cid/cir184
Abstract
The 600-mg once daily dose of rifampicin plays a key role in tuberculosis treatment. The evidence underpinning this dose is scant. A review of the historical literature identified 3 strands of reasoning. The first is the pharmacokinetic argument: The 600-mg dose yields serum drug concentrations well above the minimum inhibitory concentration of rifampicin against Mycobacterium tuberculosis. The second is the argument that adverse events may be dose related. The third is the economic argument: Rifampicin was prohibitively expensive at the time of its introduction. Recent in vitro, animal, and early bactericidal activity studies suggest that the 600-mg once daily dose is at the lower end of the dose-response curve, refuting the pharmacokinetic argument. The reduced cost and the lack of evidence of toxicity at higher daily doses remove the other arguments. To optimize tuberculosis treatment, the clinical value of higher doses of rifampicin should be tested in clinical trials.Keywords
This publication has 32 references indexed in Scilit:
- 4 Months of Rifampin Compared with 9 Months of Isoniazid for the Management of Latent Tuberculosis Infection: A Meta‐analysis and Cost‐Effectiveness Study That Focuses on Compliance and Liver ToxicityClinical Infectious Diseases, 2009
- Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in LungsAntimicrobial Agents and Chemotherapy, 2009
- Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by RifampinAntimicrobial Agents and Chemotherapy, 2007
- Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum SmearsAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial InfectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugsJournal of Antimicrobial Chemotherapy, 2003
- Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2003
- CONTROLLED CLINICAL TRIAL OF FOUR SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS Second ReportThe Lancet, 1973
- Graphic records in labour.BMJ, 1972
- Potentially Serious Side Effects of High-dose Twice-weekly RifampicinBMJ, 1971